TY - JOUR
T1 - Characteristics of Individuals in the United States Who Used Opioids during Pregnancy
AU - Nguyen, Ruby H.N.
AU - Knapp, Emily A.
AU - Li, Xiuhong
AU - Camargo, Carlos A.
AU - Conradt, Elisabeth
AU - Cowell, Whitney
AU - Derefinko, Karen J.
AU - Elliott, Amy J.
AU - Friedman, Alexander M.
AU - Khurana Hershey, Gurjit K.
AU - Hofheimer, Julie A.
AU - Lester, Barry M.
AU - McEvoy, Cindy T.
AU - Neiderhiser, Jenae M.
AU - Oken, Emily
AU - Ondersma, Steven J.
AU - Sathyanarayana, Sheela
AU - Stabler, Meagan E.
AU - Stroustrup, Annemarie
AU - Tung, Irene
AU - McGrath, Monica
N1 - Funding Information:
This work was supported by the Environmental influences on Child Health Outcomes (ECHO) program, Office of The Director, National Institutes of Health, under Award Numbers U2COD023375 (Coordinating Center), U24OD023382 (Data Analysis Center), U24OD023319 (PRO Core), and 5UH3OD023320-05 (Aschner), UG3OD023337 (Wright), UH3OD023268 (Litonjua), 4UH3OD023248-03 (Dabelea), 5UH3OD023348-05 (O'Shea), 4UH3OD023328-03 (Duarte), UH3OD023279 (Elliott), 4UH3OD023342 (Newschaffer), UH3OD023289 (Ferrara), 4UH3OD023365-03 (Hertz-Picciotto), 4UH3OD023244-03 (Hipwell), 4UH3OD023275-03 (Karagus), UH3OD023347 (Lester), UH3OD023347 (McEvoy), UH3 OD023389 (Leve), UH3 OD023349 (O'Connor), R01 HD 034568 and UH3OD 023286 (Oken), 4UH3OD023271-03 (Karr, Sathyanarayana), UH3 OD023285 (Paneth), 4UH3OD023282-03 (Gern). The authors wish to thank our ECHO colleagues and contributors, and the following ECHO program collaborators: Coordinating Center: Duke Clinical Research Institute, Durham, North Carolina: Benjamin DK, Smith PB, Newby KL; and the Data Analysis Center: Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland: Jacobson LP; Research Triangle Institute, Durham, North Carolina: Parker CB; the ECHO cohorts listed in Supplemental Data . Data utilized in these analyses may be available through approval from individual study investigators and the ECHO program. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© Copyright 2023, Mary Ann Liebert, Inc., publishers 2023.
PY - 2023/2/1
Y1 - 2023/2/1
N2 - Background: Opioid use has disproportionally impacted pregnant people and their fetuses. Previous studies describing opioid use among pregnant people are limited by geographic location, type of medical coverage, and small sample size. We described characteristics of a large, diverse group of pregnant people who were enrolled in the Environmental Influences on Child Health Outcomes (ECHO) Program, and determined which characteristics were associated with opioid use during pregnancy. Materials and Methods: Cross-sectional data obtained from 21,905 pregnancies of individuals across the United States enrolled in the ECHO between 1990 and 2021 were analyzed. Medical records, laboratory testing, and self-report were used to determine opioid-exposed pregnancies. Multiple imputation methods using fully conditional specification with a discriminant function accounted for missing characteristics data. Results: Opioid use was present in 2.8% (n = 591) of pregnancies. The majority of people who used opioids in pregnancy were non-Hispanic White (67%) and had at least some college education (69%). Those who used opioids reported high rates of alcohol use (32%) and tobacco use (39%) during the pregnancy; although data were incomplete, only 5% reported heroin use and 86% of opioid use originated from a prescription. After adjustment, non-Hispanic White race, pregnancy during the years 2010-2012, higher parity, tobacco use, and use of illegal drugs during pregnancy were each significantly associated with opioid use during pregnancy. In addition, maternal depression was associated with increased odds of opioid use during pregnancy by more than two-fold (adjusted odds ratio 2.42, 95% confidence interval: 1.95-3.01). Conclusions: In this large study of pregnancies from across the United States, we found several factors that were associated with opioid use among pregnant people. Further studies examining screening for depression and polysubstance use may be useful for targeted interventions to prevent detrimental opioid use during pregnancy, while further elucidation of the reasons for use of prescription opioids during pregnancy should be further explored.
AB - Background: Opioid use has disproportionally impacted pregnant people and their fetuses. Previous studies describing opioid use among pregnant people are limited by geographic location, type of medical coverage, and small sample size. We described characteristics of a large, diverse group of pregnant people who were enrolled in the Environmental Influences on Child Health Outcomes (ECHO) Program, and determined which characteristics were associated with opioid use during pregnancy. Materials and Methods: Cross-sectional data obtained from 21,905 pregnancies of individuals across the United States enrolled in the ECHO between 1990 and 2021 were analyzed. Medical records, laboratory testing, and self-report were used to determine opioid-exposed pregnancies. Multiple imputation methods using fully conditional specification with a discriminant function accounted for missing characteristics data. Results: Opioid use was present in 2.8% (n = 591) of pregnancies. The majority of people who used opioids in pregnancy were non-Hispanic White (67%) and had at least some college education (69%). Those who used opioids reported high rates of alcohol use (32%) and tobacco use (39%) during the pregnancy; although data were incomplete, only 5% reported heroin use and 86% of opioid use originated from a prescription. After adjustment, non-Hispanic White race, pregnancy during the years 2010-2012, higher parity, tobacco use, and use of illegal drugs during pregnancy were each significantly associated with opioid use during pregnancy. In addition, maternal depression was associated with increased odds of opioid use during pregnancy by more than two-fold (adjusted odds ratio 2.42, 95% confidence interval: 1.95-3.01). Conclusions: In this large study of pregnancies from across the United States, we found several factors that were associated with opioid use among pregnant people. Further studies examining screening for depression and polysubstance use may be useful for targeted interventions to prevent detrimental opioid use during pregnancy, while further elucidation of the reasons for use of prescription opioids during pregnancy should be further explored.
UR - http://www.scopus.com/inward/record.url?scp=85147834531&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85147834531&partnerID=8YFLogxK
U2 - 10.1089/jwh.2022.0118
DO - 10.1089/jwh.2022.0118
M3 - Article
C2 - 36350685
AN - SCOPUS:85147834531
SN - 1540-9996
VL - 32
SP - 161
EP - 170
JO - Journal of Women's Health
JF - Journal of Women's Health
IS - 2
ER -